do you still get hungry on semaglutide Why Am I Semaglutide? Causes and Solutions can semaglutide make you more

What we know: GI side effects are common but typically improve after 36 months No deaths or major safety signals through 80104 weeks across two large trials Metabolic improvements (glucose, blood pressure, lipids) are substantial and sustained Discontinuation rate: 11.3% in general obesity population (TRIUMPH-1) better than initially feared from TRIUMPH-4's 18.2% 104-week extension shows continued weight loss to 30.3% no plateau at 80 weeks What we don't know: Full 2-year safety dataset (pending publication) Whether dysesthesia resolves or persists long-term Cardiovascular outcomes (trial ongoing) Weight regain trajectory after stopping Very rare adverse events requiring broader use to detect The bottom line: Retatrutide offers superior weight loss compared to existing medications and TRIUMPH-1's 11.3% discontinuation rate suggests the tolerability picture is better than TRIUMPH-4's osteoarthritis cohort implied

In vivo , studies directly modelling pulmonary fibrosis remain sparse and have shown converse results

Not approved by the Therapeutic Goods Administration (TGA) for any clinical use

10.1038/nature12820 20

Zonas recomendadas del abdomen para la inyeccin La seleccin apropiada del sitio de inyeccin en el abdomen es esencial para optimizar la absorcin del medicamento y prevenir complicaciones locales